CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
UREA C 13	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Isotopic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Purity/ Chromatographic system: Change **Flow rate**: Flow rate to: **Flow rate**: 1 mL/min
BLACK CUMIN SEED THYMOQUINONE OIL	SPECIFIC TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Fats and Fixed Oils* ?401?, *Procedures*, *Fatty Acid Composition/Table 2*: Change Linoleic to: Linoleic acid
CRANBERRY FRUIT DRY JUICE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *USP Reference Standards* ?11?: Change USP Procyanidin A_2 RS to: USP Procyanidin A2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZIPRASIDONE CAPSULES	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	RS In *Organic Impurities/Solution B*: Change potassium hydroxide to: potassium hydroxide solution AND In *Organic Impurities/Analysis*: Change 449.40 to: 449.39
VALGANCICLOVIR HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Organic Impurities/Table 3*/footnote c: Change 2-[(2-Amino-6-oxo-1,6-dihydro-9*H* -purin-9-yl)methoxy]-2-hydroxypropyl methyl-L-valinate hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ARIPIPRAZOLE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	to: 3-[(2-Amino-6-oxo-1,6-dihydropurin-9-yl)methoxy]-2-hydroxypropyl L-valinate hydrochloride. In *Dissolution <711>/Test 1/ Procedure/ Chromatographic procedure/Analysis*: Change Result = $(R_U/R_S) \times C_S \times V \times (1/L) \times 100$ to: Result = $(R_U/R_S) \times C_S \times V \times D \times (1/L) \times 100$ AND Add *D* = dilution factor of the *Sample solution*, 2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CRANBERRY FRUIT DRY JUICE	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A./Standard solution B*: Change USP Procyanidin A_2 RS to: USP Procyanidin A2 RS AND In *A./System suitability/Suitability requirements/Derivatization reagent B/White light*: Change *Standard solution B* exhibits two brown bands in the upper-half section corresponding to procyanidin A_2 and epicatechin. *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution C exhibits two brown bands in the upper-half section corresponding in R_F and color to procyanidin A_2 and epicatechin in *Standard solution B*. *Standard solution C* also exhibits a series of faint or indistinct brown bands of differing intensities below procyanidin A_2 in the lower-half section. to: *Standard solution B* exhibits two brown bands in the upper-half section

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								corresponding to procyanidin A2 and epicatechin. *Standard solution C* exhibits two brown bands in the upper-half section corresponding in R_F and color to procyanidin A2 and epicatechin in *Standard solution B*. *Standard solution C* also exhibits a series of faint or indistinct brown bands of differing intensities below procyanidin A2 in the lower-half section. AND In *A*./

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acceptance criterial Derivatization reagent B/*White light*: Change The *Sample solution* exhibits two faint brown bands corresponding in R_F to procyanidin A_2 and epicatechin in *Standard solution B*. The *Sample solution* also exhibits a series of faint or indistinct brown bands of differing intensities in the lower-half section, corresponding to the same bands in *Standard solution C*. No bands corresponding

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in R_F to epigallocate chin-3-*O*-gallate, procyanidin B_2, or procyanidin B_1 appear below procyanidin A_2. to: The *Sample solution* exhibits two faint brown bands corresponding in R_F to procyanidin A2 and epicatechin in *Standard solution B*. The *Sample solution* also exhibits a series of faint or indistinct brown bands of differing intensities in the lower-half section, corresponding to the same

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bands in *Standard solution C*. No bands corresponding in R_F to epigallocatechin-3-*O*-gallate, procyanidin B2, or procyanidin B1 appear below procyanidin A2. AND In *C./Acceptance criteria/Profile at 520 nm*: Change cyanidin-3-*O*-arabinose, to: cyanidin-3-*O*-arabinoside, AND In *C./Acceptance criteria/Profile at*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								520 nm: Change peon idin-3-*O*-arabinose to: peon idin-3-*O*-arabinoside
ZIPRASIDONE CAPSULES	ASSAY	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Procedure/Analysis*: Change 449.40 to: 449.39
AZITHROMYCIN	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Organic Impurities/Table 2*: Change: 3?-*N*-{[4-(Acetylamino)phenyl]sulfonyl}-3?-demethylazithromycin[m] to: 3'-*N*-D emethyl-3'-*N*-[(4-methylphenyl)sulfonyl]azithr

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								omycin[m] AND In *Organic Impurities*/*Table 2*/footnote m: Change (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-acetamidophenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-?-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								an-15-one. to: (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-methylphenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-ß-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION	*Assay*	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Chromatographic system* and *Procedure*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM ALGINATE	ASSAY	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	*C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS, on the anhydrous basis, in the *Standard preparation*; to: *C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS in the *Standard preparation*; In *Procedure/Analysis*: Change Result = $(V_2 \times N \times W_E)/(W \times D)$ to: Result = $(V_2 \times N \times W_E \times 10)/(W \times D)$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOSAMPRENAVIR CALCIUM TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Dissolution* ?711?/*Medium*: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows. Dissolve 2.67 g of sodium acetate in 100 mL of water. Add 13.3 mL of glacial acetic acid and then dilute with water to 1000 mL; 900 mL.
ZIPRASIDONE HYDROCHLOR	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Organic Impuri*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE								*ties*/*Solution B*: Change Acetonitrile, methanol, and *Buffer* (55:5:40). Adjust with potassium hydroxide TS to a pH of 6.0. to: Acetonitrile, methanol, and *Buffer* (55:5:40). Adjust with potassium hydroxide solution to a pH of 6.0. AND In both equations in *Organic Impuri ties*/*Analysis*: Change 449.40 to: 449.39
REAGENTS AND REFERENCE	*Solutions*/*Test Solutions and Indicator*	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	Change Prepare this solution by one

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLES	*Solutions/Starch TS*							of the following procedures: to: Prepare this solution by one of the following procedures. Apply the *Test for sensitivity* to confirm suitability for freshly or previously prepared solutions or commercially bought solutions. AND In *Storage*: Delete Use the *Test for sensitivity* to confirm suitability for use. AND In *Procedure with No Preservative*: Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Apply the *Test for sensitivity* to confirm suitability for freshly or previously prepared solutions. AND In *Test for sensitivity*: Delete Use the *Test for sensitivity* to confirm suitability for use. AND In *Procedure with Salicylic Acid as Preservative*: Change Mix 1 g of soluble starch with 50 mL of cold water to: Mix 1 g of soluble starch with 5 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BLACK CUMIN SEED THYMOQUINONE OIL	DEFINITION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	cold water Change carvacol to: carvacrol
CRANBERRY FRUIT DRY JUICE	COMPOSITION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Content of Pr* /*Standard stock solution*: Change USP Procyanidin A_2 RS to: USP Procyanidin A2 RS AND In *Content of Pr* /*Analysis*: Change Use the absorbance recorded for *Standard solutions 1–5* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obtain a calibration curve (absorbance vs. concentration, in µg/mL, of procyanidin A_2) and perform a linear regression analysis. Determine the concentration (*C*), in µg/mL, of total proanthocyanidins as procyanidin A_2 in the *Sample solution*. to: Use the absorbance recorded for *Standard solutions 1–5* to obtain a calibration curve (absorbance vs. concentration, in µg/mL, of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								procyanidin A2) and perform a linear regression analysis. Determine the concentration (*C*), in µg/mL, of total proanthocyanidins as procyanidin A2 in the *Sample solution*. AND In *Content of Pr* */Analysis*: Change *C* = concentration of the *Sample solution* as procyanidin A_2 from the regression line (µg/mL) to: *C* = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample solution* as procyanidin A2 from the regression line (µg/mL) AND In *Content of Pr*
ZIPRASIDONE CAPSULES	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	*/Acceptance criteria*: Change procyanidin A_2 to: procyanidin A2 In *Dissolution* ?711?/*Test 1*/*Tier 1*/*Phosphate buffer, pH 7.5*: Change sodium hydroxide to: sodium hydroxide solution AND In *Dissolution* ?711?/*Test*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1/*Tier 1*/*Analysis*: Change 449.40 to: 449.39 AND In *Dissolution* ?711?/*Test 1*/*Tier 2*/*Solution A* and *Solution B*: Change sodium hydroxide to: sodium hydroxide solution AND In *Dissolution* ?711?/*Test 2*/*Tier 2*/*Analysis*: Change 449.40 to: 449.39 AND In *Dissolution* ?711?/*Test*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3/*Tier 2*/*Analysis*: Change 449.40 to: 449.39
AZITHROMYCIN	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin Related Compound F RS: Change 762.97 to: 762.98 AND In USP Desosaminylazithromycin RS: Change 590.79 to: 590.80

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMANTADINE HYDROCHLORIDE	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A.*: Change *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197A, 197K, and 197S to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197A, 197K, or 197S **Procedure for 197S**
CRANBERRY FRUIT DRY JUICE	DEFINITION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	Change procyanidin A_2 to: procyanidin A2
OCTOCRYLENE	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A./ Acceptance criteria*: Change NMT 3.0%, calculated on the as-is basis to: Absorptivities, calculated on

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the as-is basis, do not differ by more than 3.0%.
AZITHROMYCIN	CHEMICAL INFORMATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	Change 748.98 to: 749.00 AND Change 767.00 to: 767.01 AND Change 785.02 to: 785.03
TOPICAL AND TRANSDERMAL DRUG PRODUCTS—PRODUCT QUALITY TESTS	SPECIFIC TESTS FOR TDS	*USPNF Online*	Online	28-Jul-2023	1-Dec-2023	*NA*	*NA*	In *Release Liner Peel Test*: Change The product fails the test if the mean peel force is outside the acceptable range determined during product development. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PIPERACILLIN	SPECIFIC TESTS	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	The product fails the test if the overall mean peel force is outside the acceptable range determined during product development. In *Sterility Tests* ?71?: Change Where the label states that Piperacillin is sterile or that it must be subjected to further processing during the preparation of injectable dosage forms, it meets the requirements when tested as directed in *Test for Sterility of the Product to Be Examined*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Membrane Filtration. to: Where the label states that Piperacillin is sterile, it meets the requirements when tested as directed in *Test for Sterility of the Product to Be Examined*, *Membrane Filtration*.
AZITHROMYCIN FOR INJECTION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*USPNF 2024 Issue 2*	In *USP Reference Standards* ?11?/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin *N*-oxide RS: Change 764.98

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 765.00 AND In USP *N* -Demethylazithromycin RS: Change 734.96 to: 734.97 AND In USP Desosaminylazithromycin RS: Change 590.79 to: 590.80
TRIAZOLAM TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	In *Standard solution*: Change Tablet/mg to: mg/Tablet
TRIMETHOBENZAMIDE HYDROCHLORIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	Change *N*-[*p* -[2-(Dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxy benzamide monohydrochloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *N* -[4-[2-(Dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride
PURIFIED SILICEOUS EARTH	IMPURITIES	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	In *Leachable Arsenic/ Analysis*: Change A 3.0-mL portion of the *Sample solution* meets the requirements in *Arsenic* ?211?, *Procedures*, *Procedure*. to: A 3.0-mL portion of the *Sample solution* meets the requirements in *Arsenic* ?211?, *Procedures*, *Procedure 1*.
CLOMIPHENE CITRATE	IM PUR	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	In *Table 2*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	ITIES/*Organic Impurities*							Clomiphene related compound A 0.87 – 2.0 to: Clomiphene related compound A 0.87 1.0 2.0
CHLORTETRACYCLINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	Change 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride to: (4*S*,4a*S*,5a*S*,6*S*,12a*S*)-7-Chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-car

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AZITHROMYCIN FOR INJECTION	IMPURITIES	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*USPNF 2024 Issue 2*	boxamide monohydrochloride In footnote m in *Table 2*: Change (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-acetamidophenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-?-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-methylphenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-ß-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
REAGENTS AND REFERENCE TABLES	*Reagent Specifications/ Tosylchloramid*	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	Change 127-65-1 to: 7080-50-4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POLYVINYL ALCOHOL	*e Sodium* IMPURITIES	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	In *Limit of Methanol (Methyl Alcohol) and Methyl Acetatel Analysis*: Change C_U = concentration of methanol (methyl alcohol) or methyl acetate in the *Sample solution* (mg/mL) to: C_U = concentration of Polyvinyl Alcohol in the *Sample solution* (mg/mL)
SITAGLIPTIN PHOSPHATE	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Analysis*: Change C_S = concentration of USP Sitagliptin Phosphate in the *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/mL) to: C_S = concentration of USP Sitagliptin Phosphate RS in the *Standard solution* (mg/mL)
TIOCONAZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In USP Tioconazole Related Compound A RS: Change 389.73 to: 389.72 AND In USP Tioconazole Related Compound B RS: Change 458.62 to: 458.60 AND In USP Tioconazole Related Compound C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS: Change $C_{16}H_{13}BrCl_2N_2OS \cdot HCl$ 468.63 to: $C_{16}H_{12}BrCl_3N_2OS \cdot HCl$ 503.06
ATORVASTATIN CALCIUM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In USP Atorvastatin Related Compound B RS: Change 1155.34 to: 1155.36
CALCIUM ASCORBATE	ASSAY/*Procedure*	*USPNF Online*	Online	30-Jun-2023	1-Aug-2023	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of calcium ascorbate dihydrate, 426.43 to: M_{r1} = molecular weight of calcium ascorbate dihydrate, 426.34

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATORVASTATIN CALCIUM TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of atorvastatin, 558.64 M_{r2} = molecular weight of atorvastatin calcium, 1155.34 to: M_{r1} = molecular weight of atorvastatin, 558.65 M_{r2} = molecular weight of atorvastatin calcium, 1155.36
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	Change USP Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) RS (USP Methacrylic Acid Copolymer,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Type C RS) to: USP Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) RS (USP Methacrylic Acid Copolymer Type C RS)
DIGOXIN TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Chromatographic system*: Change **Column:** 4.2-mm × 25-cm; 5-?m packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
RISEDRONATE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Buffer stage*/*Analysis*: Change Calculate the percentage of the labeled

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								amount of risedronate sodium ($C_7H_{10}NNaO_7P_7$) dissolved: to: Calculate the percentage of the labeled amount of risedronate sodium ($C_7H_{10}NNaO_7P_2$) dissolved:
ATORVASTATIN CALCIUM TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of atorvastatin, 558.64 M_{r2} = molecular weight of atorvastatin calcium, 1155.34 to: M_{r1} = molecular weight of atorvastatin,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								558.65 M_{r2} = molecular weight of atorvastatin calcium, 1155.36
ATORVASTATIN CALCIUM TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Test 1*, *Test 3*, *Test 4*, *Test 5*, and *Test 6*/*Analysis*: Change M_{r1} = molecular weight of atorvastatin, 558.64 M_{r2} = molecular weight of atorvastatin calcium, 1155.34 to: M_{r1} = molecular weight of atorvastatin, 558.65 M_{r2} = molecular weight of atorvastatin calcium, 1155.36
METHACRYLIC	IDENTIFICATIO	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ACID AND ETHYL ACRYLATE COPOLYMER	N/*A*.							USP Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) RS to: USP Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) RS (USP Methacrylic Acid Copolymer Type C RS)
MILBEMYCIN OXIME	CHEMICAL INFORMATION	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	Change 541.68 Milbemycin B, 5-*O* -demethyl-28-deoxy-25-methyl-6,28-epoxy-23-hydroxyimino-, [6*R*,23*S*,25*S*(*E*)]-; (2?*E*,4*E*,5?*S*,6*R*,6?*S*,8*E*,11*R*,13*R*,15*S*,17?*R*,20?*R*,20?*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-3?,4?,5?,6,6?,7,10,11,14,15,17?,20,20?,20?-tetradecahydro-20?-hydroxy-5?,6?,6,8,19-pentamethylspiro[11,15-meth ano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2?-[2*H*]pyran]-17-one 20-oxime. to: 541.69 Milbemycin B, 5-demethoxy-28-deoxy-6,28-epoxy-5-(hydroxyamino)-25-methyl-, (6*R*,25*R*)-; (2*R*,2a?*E*,2a1?*S*,4?*E*,5*S*,6*R*,6?*R*,8?*E*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,11?*R*,15?*S* ,17a?*R*,20?*Z* ,20a?*R*)-2a1?-Hydroxy- 20?-(hydroxyimi no)-5,6,6?,8?,19 ?-pentamethyl-2 a1?,3,4,5,6,6?,7 ?,10?,11?,14?,1 5?,17a?,20?,20 a?-tetradecahyd ro-2?*H*,17?*H* -spiro[pyran-2,1 3?-[11,15]metha no[1,5]dioxacycl ooctadecino[9,8 ,7-*cd*]benzofuran]-17 ?-one. AND Change 555.70 Milbemycin B, 5-*O* -demethyl-28-d eoxy-25-ethyl-6, 28-epoxy-23-hy droxyimino-, [6*R*,23*S*,25*S*(*E*)]-; (2?*E*,4*E*,5?*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,6*R*,6?*S*,8*E*,11*R*,13*R*,15*S*,17?*R*,20?*R*,20?*S*)-6?-ethyl-3?,4?,5?,6,6?,7,10,11,14,15,17?,20,20?,20?-tetradecahydro-20?-hydroxy-5?,6,8,19-tetramethylspiro[1
								H,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2?-[2*H*]pyran]-17-one 20-oxime. to: 555.71 Milbemycin B, 5-demethoxy-28-deoxy-6,28-epoxy-25-ethyl-5-(hydroxyamino)-, [6*R*,25*R*]-;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATOVAQUONE IMPURITIES		*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	(2*R*,2a?*E*,2a1?*S*,4?*E*,5*S*,6*R*,6?*R*,8?*E*,11?*R*,15?*S*,17a?*R*,20?*Z*,20a?*R*)-6-Ethyl-2a1?-hydroxy-20?-(hydroxyimino)-5,6?,8?,19?-tetramethyl-2a1?,3,4,5,6,6?,7?,10?,11?,14?,15?,17a?,20?,20a?-tetradecahydro-2?*H*,17?*H*-spiro[pyran-2,13?-[11,15]methano[1,5]dioxacyclooctadecino[9,8,7-*cd*]benzofuran]-17?-one. Change **Related Compounds System suitability solution** and **Sample**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Prepare as directed in the *Assay*. **Analysis Samples**: *System suitability solution* and *Sample solution* Using the chromatograms of the *Sample solution* and the *System suitability solution*, calculate the percentage of atovaquone related compounds in the portion of Atovaquone taken: to: **Organic Impurities Mobile phase**, **Diluent**,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	**System suitability solution**, **Standard solution**, **Sample solution**, **Chromatographic system** and **System suitability**: Proceed as directed in the *Assay*. **Analysis Sample**: *Sample solution* Calculate the percentage of atovaquone related compounds in the portion of Atovaquone taken: Change USP Atorvastatin Related Compound H

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS (lactone impurity) to: USP Atorvastatin Related Compound H RS Also known as Lactone impurity; AND Change USP Atorvastatin Related Compound I RS (acetonide impurity) to: USP Atorvastatin Related Compound I RS Also known as Acetonide impurity;
OSELTAMIVIR PHOSPHATE	IM PUR ITIES/*Organic Impuri*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In *System suitabil ity*/*Suitability re*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ties/*Procedure 3: Limit Of Tributyl Phosphine Oxide*							*quire ments*/*Relative standard deviation*: Change NMT 10.0% for the tributyl phosphine oxide and osteltamivir phosphate peaks to: NMT 10.0% for the tributyl phosphine oxide and oseltamivir phosphate peaks
METHYLPHENIDATE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In USP Methylphenidate Related Compound A RS: Change ?-Phenyl-2-piperidineacetic acid hydrochloride. to: (*RS*)-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LINEZOLID TABLETS	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	2-Phenyl-2-[(*RS*)-piperidin-2-yl]acetic acid hydrochloride. In *Sensitivity solution*: Change 0.5 ug/mL of USP Linezolid RS from *Standard solution* in *Diluent* to: 0.5 ?g/mL of USP Linezolid RS from *Standard solution* in *Diluent*

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Page 4

- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »